Amgen Research (Munich) Gmbh

Christina Heitmueller

Peter Kufer

Roman Kischel

Gerhard Zugmaier

Marion Subklewe

The present invention provides a bispecific construct comprising a first binding domain specifically binding to CD33 and a second binding domain specifically binding to CD3 for use in a method for the treatment of myeloid leukemia, wherein the construct is administered for a maximal period of 14 days followed by a period of at least 14 days without administration of the construct. Moreover, the invention provides a method for the treatment of myeloid leukemia comprising the administration of a therapeutically efficient amount of such bispecific construct and the use of such bispecific construct for the preparation of a pharmaceutical composition for the treatment of myeloid leukemia.

Growing community of inventors

Munich, Germany

Christina Heitmueller